Soleno Therapeutics [SLNO] vs Blueprint Medicines [BPMC] Detailed Stock Comparison
Soleno Therapeutics
NASDAQ
Loading...
Blueprint Medicines
NASDAQ
Loading...
TLDR: Quick Comparison Summary
Based on 18 vital metrics comparison: Soleno Therapeutics wins in 7 metrics, Blueprint Medicines wins in 6 metrics, with 0 ties. Soleno Therapeutics appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Soleno Therapeutics | Blueprint Medicines | Better |
|---|---|---|---|
| P/E Ratio (TTM) | N/A | -120.99 | N/A |
| Price-to-Book Ratio | 17.58 | 24.43 | Soleno Therapeutics |
| Debt-to-Equity Ratio | 22.73 | 208.50 | Soleno Therapeutics |
| PEG Ratio | -37.06 | -137.72 | Blueprint Medicines |
| EV/EBITDA | -19.80 | -53.14 | Blueprint Medicines |
| Profit Margin (TTM) | 0.00% | -27.70% | Soleno Therapeutics |
| Operating Margin (TTM) | 0.00% | -27.50% | Soleno Therapeutics |
| Return on Equity | -105.54% | -47.71% | Blueprint Medicines |
| Return on Assets (TTM) | -52.40% | -9.75% | Blueprint Medicines |
| Free Cash Flow (TTM) | $-69.31M | $-197.22M | Soleno Therapeutics |
| 1-Year Return | 79.37% | 12.60% | Soleno Therapeutics |
| Price-to-Sales Ratio (TTM) | N/A | 14.89 | N/A |
| Enterprise Value | $4.00B | $8.42B | Blueprint Medicines |
| EV/Revenue Ratio | N/A | 14.97 | N/A |
| Gross Profit Margin (TTM) | N/A | 98.12% | N/A |
| Revenue per Share (TTM) | N/A | $9 | N/A |
| Earnings per Share (Diluted) | $-4.74 | $-2.51 | Blueprint Medicines |
| Beta (Stock Volatility) | -2.56 | 0.83 | Soleno Therapeutics |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Soleno Therapeutics vs Blueprint Medicines Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Soleno Therapeutics | 4.62% | -4.24% | -3.41% | 7.99% | 64.01% | 80.16% |
| Blueprint Medicines | 0.00% | 0.12% | 1.05% | 53.79% | 15.63% | 48.46% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Soleno Therapeutics | 79.37% | 2,769.34% | 193.58% | -56.94% | -72.62% | -72.62% |
| Blueprint Medicines | 12.60% | 149.54% | 73.38% | 370.76% | 598.65% | 598.65% |
Performance & Financial Health Analysis: Soleno Therapeutics vs Blueprint Medicines
| Metric | SLNO | BPMC |
|---|---|---|
| Market Information | ||
| Market Cap | $4.44B | $8.37B |
| Market Cap Category | Mid cap | Mid cap |
| 10 Day Avg. Volume | 980,930 | 5,799,940 |
| 90 Day Avg. Volume | 1,400,677 | 4,343,357 |
| Last Close | $82.35 | $129.46 |
| 52 Week Range | $41.50 - $90.32 | $73.04 - $129.65 |
| % from 52W High | -8.82% | -0.15% |
| All-Time High | $742.50 (Mar 02, 2015) | $129.65 (Jul 16, 2025) |
| % from All-Time High | -88.91% | -0.15% |
| Growth Metrics | ||
| Quarterly Revenue Growth | N/A | 0.56% |
| Quarterly Earnings Growth | N/A | -0.99% |
| Financial Health | ||
| Profit Margin (TTM) | 0.00% | -0.28% |
| Operating Margin (TTM) | 0.00% | -0.28% |
| Return on Equity (TTM) | -1.06% | -0.48% |
| Debt to Equity (MRQ) | 22.73 | 208.50 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $4.79 | $5.30 |
| Cash per Share (MRQ) | $5.75 | $8.92 |
| Operating Cash Flow (TTM) | $-89,320,000 | $-145,552,000 |
| Levered Free Cash Flow (TTM) | $-33,976,876 | $-20,779,750 |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | N/A | N/A |
Valuation & Enterprise Metrics Analysis: Soleno Therapeutics vs Blueprint Medicines
| Metric | SLNO | BPMC |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | N/A | -120.99 |
| Forward P/E | -37.06 | -137.72 |
| PEG Ratio | -37.06 | -137.72 |
| Price to Sales (TTM) | N/A | 14.89 |
| Price to Book (MRQ) | 17.58 | 24.43 |
| Market Capitalization | ||
| Market Capitalization | $4.44B | $8.37B |
| Enterprise Value | $4.00B | $8.42B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | N/A | 14.97 |
| Enterprise to EBITDA | -19.80 | -53.14 |
| Risk & Other Metrics | ||
| Beta | -2.56 | 0.83 |
| Book Value per Share (MRQ) | $4.79 | $5.30 |
Financial Statements Comparison: Soleno Therapeutics vs Blueprint Medicines
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | SLNO | BPMC |
|---|---|---|
| Revenue/Sales | $0 | $149.41M |
| Cost of Goods Sold | N/A | $2.80M |
| Gross Profit | N/A | $146.61M |
| Research & Development | $13.52M | $91.89M |
| Operating Income (EBIT) | $-42.78M | $-41.09M |
| EBITDA | $-38.94M | $23.55M |
| Pre-Tax Income | $-43.77M | $1.29M |
| Income Tax | N/A | $789,000 |
| Net Income (Profit) | $-43.77M | $496,000 |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | SLNO | BPMC |
|---|---|---|
| Cash & Equivalents | $81.33M | $122.25M |
| Total Current Assets | $308.92M | $702.07M |
| Total Current Liabilities | $15.73M | $250.58M |
| Long-Term Debt | $52.20M | $409.17M |
| Total Shareholders Equity | $232.26M | $342.13M |
| Retained Earnings | $-496.03M | $-2.41B |
| Property, Plant & Equipment | $2.78M | $97.66M |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | SLNO | BPMC |
|---|---|---|
| Operating Cash Flow | $-27.86M | $13.41M |
| Capital Expenditures | $-5,000 | $-1.83M |
| Free Cash Flow | $-32.76M | $-56.31M |
| Debt Repayment | N/A | $-4.11M |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | SLNO | BPMC |
|---|---|---|
| Shares Short | 5.87M | 3.13M |
| Short Ratio | 3.74 | 0.62 |
| Short % of Float | 0.13% | 0.05% |
| Average Daily Volume (10 Day) | 980,930 | 5,799,940 |
| Average Daily Volume (90 Day) | 1,400,677 | 4,343,357 |
| Shares Outstanding | 45.70M | 63.71M |
| Float Shares | 41.23M | 60.00M |
| % Held by Insiders | 0.02% | 0.01% |
| % Held by Institutions | 1.11% | 1.09% |
Dividend Analysis & Yield Comparison: Soleno Therapeutics vs Blueprint Medicines
| Metric | SLNO | BPMC |
|---|---|---|
| Last 12-Month Dividend | N/A | N/A |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | N/A | N/A |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | N/A | N/A |
| Ex-Dividend Date | N/A | N/A |